Obicetrapib
Meta-analysis of nine RCTs in 3,516 patients confirms obicetrapib lowers LDL-C by 37% and Lp(a) by 41% with no excess adverse events (Cardiol Rev 2025)
Original title: Safety and Efficacy of Obicetrapib for Atherogenic Lipid Reduction: A Systematic Review and Meta-Analysis
A systematic review and meta-analysis of nine randomised controlled trials (3,516 patients) of obicetrapib versus placebo in adults with dyslipidaemia. Obicetrapib reduced LDL-C by a mean of 37.45% (95% CI, 33.74 to 41.17), apoB by 24.63%, non-HDL-C by 30.96%, triglycerides by 7.5% and Lp(a) by 40.85%, while raising HDL-C by 150.06%. No significant increase in adverse events was observed compared with placebo. Another pooling of the same trial evidence base as several similar meta-analyses, with a consistent effect-size picture across atherogenic and anti-atherogenic lipid fractions.
Original abstract
Cardiovascular risk remains elevated in hyperlipidemic patients despite standard lipid-lowering therapy, with dyslipidemia persisting as a key contributor. We conducted a meta-analysis to investigate the effectiveness and safety of obicetrapib, a selective cholesteryl ester transfer protein inhibitor, in improving lipid parameters and reducing residual cardiovascular risk in patients with dyslipidemia. The protocol of this meta-analysis was registered with PROSPERO (CRD420251102986). We searched MEDLINE (PubMed), Embase, the Cochrane Library, and trial registers from inception till July 2025 to identify randomized controlled trials investigating obicetrapib in adult patients with dyslipidemia. Our primary outcome was the mean percentage change from baseline in low-density lipoprotein cholesterol levels. Risk ratios and mean differences (MDs) were pooled under a random-effects model. Nine randomized controlled trials (n = 3516) were included in this review. Obicetrapib documented significant reductions in low-density lipoprotein cholesterol [MD: -37.45% (95% confidence interval (CI): -41.17 to -33.74)], apolipoprotein B [MD: -24.63% (95% CI: -28.42 to -20.84)], non-high-density lipoprotein cholesterol [MD: -30.96% (95% CI: -33.76 to -28.16)], triglyceride [MD: -7.5% (95% CI: -11.09 to -3.91)], and lipoprotein(a) [MD: -40.85% (95% CI: -54.79 to -26.90)] compared to placebo. High-density lipoprotein cholesterol levels significantly increased [MD: 150.06% (95% CI: 138.52-161.61)]. Obicetrapib was not associated with a significantly increased risk of adverse events compared to placebo. Obicetrapib significantly improved the lipid profile, with marked reductions in atherogenic lipoproteins and increases in HDL-related parameters with no major safety concerns observed. These results support the inclusion of obicetrapib in broader lipid management approaches aimed at reducing cardiovascular risk.
HDL biologyLDL and apoBlipoprotein aobicetrapib
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.